HIV

Lack of access will result in needless HIV infections, campaigners say.

The World Health Organization reports alarming levels of HIV first-line antiretroviral therapies resistance in Africa, Asia and the Americas, particularly in women and children, and highlights the need to expedite the transition to dolutegravir-based regimens

A facility is widely supported but cannot be built under current law.

A potential early signal for neural-tube defects associated with dolutegravir exposure at conception was previously revealed.

DTG has potency, resistance, and side-effect benefits over EFV, and there are widespread plans to rapidly expand its use in low- and middle-income countries.

Dolutegravir has a high genetic barrier to resistance and is available in a fixed-dose combination and at low cost.

A study highlights the differences between type 1 and type 2 myocardial infarction and shows high mortality in the HIV-infected population, particularly after type 2 which is associated with renal dysfunction, high viral load and older age

The HIV Disability Questionnaire (HDQ) is a useful tool for use in the UK, researchers find.

UM’s Adam Burgener explains why the microbiome should be considered when studying HIV risk.

Dr. Cohen, whose HPTN 052 was named Science’s Breakthrough of the Year in 2011, breaks down the future of HIV treatment and prevention.

The IAS 2019 Conference on HIV Science brought the promise of new treatments, ways of delivering prevention, and a reminder of just how much there is to do to end the epidemic.

Some promising signs have been identified.

Every-other-day regimen is comparable.

Are we getting closer to an effective vaccine?